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squarely at the anti-infective and an-Innovations
ticancer markets, where drug resis-
tance is a concern. “We’re starting
with a proven drug with known phar-Kosan Biosciences
macological qualities where cells
have become resistant and buildingBetter Chemistry through Genetics
something with enhanced activity,”
adds Katz.
The other, more recently devel-
ing the PKS biosynthetic route in E. oped approach is the chemo-bio-
coli now. chemosynthetic route for producing
Gene manipulation and chemo-
“I call it chemo-bio-chemosynthe-
sis,” says David C. Myles, Executive
Director, Chemistry, at Kosan Bio- novel polyketides. “This really takes
sciences, describing a triune pro- biosynthesis complete the Kosan chemobiosynthesis to the next
duction strategy for novel polyke- technology platform. Through PKS level,” says Myles, describing the
tides, a source of pharmaceuticals gene manipulation, Kosan adds re- process of manipulating PKS genes
found in nature. Hayward, Califor- active sites to polyketides with pre- to synthesize small fragments of
nia-based Kosan is on a mission viously chemically dead sites not polyketides that are readily amena-
to improve existing polyketides and amenable to chemical manipulation. ble to chemical modification and
to develop new polyketide analogs “The highly functionalized nature of then assembling those fragments to
as part of its drug development polyketides means that as you as- make large complex polyketides.program. semble the molecules chemically, Mimicking Natural ModularPolyketides are not new. About you may also create stereochemis- Chemistry10,000 polyketides have been iso- try,” Myles says to explain why Kosan got its start—and itslated, mainly in soil microorganisms, applying combinatorial methods is name—in 1995 from cofoundersfrom which approximately 50 com- difficult with polyketides. “This way Santi and Chaitan Khosla, PhD, Pro-mercial pharmaceutical products, we give ourselves an opportunity to fessor of Chemical Engineering,including antibiotics, anticancer do chemistry by first doing genet- Chemistry, and Biochemistry atdrugs, and immunosuppressants, ics,” says Katz. Stanford University. Some of thehave been derived. What is new is Kosan’s approach to polyketide early knowledge was contributed byhow Kosan is building on the inher- chemobiosynthesis comes in two Leonard Katz, then at Abbott Labo-ent biological activities found in
ratories, about a natural system ofpolyketides to make better drug
modular chemistry for creating com-candidates.
plex molecules.“The technology itself isFundamental to Kosan’s efforts
“The technology itself is amena-is the structure of the polyketide bio- amenable to combinato- ble to combinatorial biosynthesis,synthesis enzymes, polyketide syn- rial biosynthesis, where where by mixing and matching thesethases (PKS). By manipulating the
genes you could create entirely newby mixing and matchinggenes encoding PKS enzymes, the
libraries of polyketides,” says Santi.type, order, and number of PKS en- these genes you could Yet early on, Khosla and Santi real-zymes is altered. The end result is create entirely new li- ized that the company’s technologyto make specific and, hopefully,
would have added results in thebraries of polyketides.”medically relevant improvements to
pharma business, scientifically andknown polyketides or novel polyke- –Daniel V. Santi, Kosan otherwise, by modifying polyketidetides altogether. cofounder and CEO drugs already validated in terms ofChemobiosynthesis over
their potential as pharmaceuticals.Combichem
They set out on their quest to“What we do is ‘chemistry by genet-
flavors. One involves a chemical modify these drugs either in terms ofics,’” says Leonard Katz, Vice Presi-
phase where a small molecule is changing their properties to improvedent, Biological Sciences at Kosan.
synthesized that mimics an interme- efficacy or in the production pro-One strategy is to transfer the ge-
diate in the biosynthesis of a known cess itself, where yields could benetic instructions for making a poly-
polyketide. The small molecule is boosted significantly.ketide out of its natural source,
first fed to a genetically modified or- High-Value Pharmaceuticalwhere it is usually produced in small
ganism. “The result of that fermenta- Targetsquantities, into another more pro-
tion process is an unnatural natural Kosan is focused fairly exclusivelyductive microorganism. Kosan’s fa-
product,” says Myles. “We then take on a few high-value pharmaceuticalvored biological workhorse is Strep-
that product and use the chemical targets. About 15%–20% of its re-tomyces coelicolor with efforts into
handle we’ve engineered into the search budget is devoted to further-developing E. coli as a model organ-
polyketide—the legacy of the small ing the underlying technology. Itsism now quickly ramping up. “A ma-
molecule fed into the fermentation lead program includes the epothi-jor advantage of moving the genes
process—and modify it chemically lones, polyketide products that haveinto E. coli is the shorter life cycle
to achieve any of the properties a mechanism identical to Taxol butcompared with soil microorgan-
we’re after,” he says. Clinically, Ko- with efficacy on Taxol-resistant can-isms,” says Daniel V. Santi, MD,
PhD, Kosan’s CEO. Kosan is pursu- san is targeting this approach cer cells. Kosan also has a collabo-
Chemistry & Biology
850
rative project with Johnson & John- Kosan has an ongoing agreement phase II testing from Novartis and
Bristol Myers Squibb. “BMS has hadson Pharmaceutical Research & with MSKCC directed toward con-
tinuing analog synthesis, givingDevelopment, LLC, developing ke- a number of responses in different
tumors with their epothilone,” saystolides, a next-generation antibiotic. them access to new chemistries and
new synthetic routes. “One of theKosan is also joining efforts with Santi. “We’ll use those results to
guide our phase II trials.”Meiji Seika Kaisha, Ltd, for antibiotic most important goals of my lab is to
find new epothilones with valuabledrug development. Two other anti- Combinatorial Polyketide
Librariescancer programs include produc- activities,” says Danishefsky, who is
also a member of Kosan’s Scientifiction of discodermolide, a compound In June 2002, Kosan was awarded
a $2 million Advanced Technologywith cancer-fighting properties found Advisory Board. He adds, “If, as we
expect to be the case, a clear alter-in an unculturable microorganism in Program grant from the National In-
stitute of Standards and Technologysea sponges, and developing gelda- native to epothilone D (i.e., a
‘backup’ compound) would comenamycin polyketides to bind to a to support what Katz calls “morph-
ing” polyketide synthase genes byheat-shock protein called Hsp90 forth, another goal would be the syn-
thesis of that compound by purelyand deplete cells of signal transduc- combinatorial biosynthesis. “This
grant is to take the separate mod-tion proteins. chemical means, if need be.”
According to Danishefsky, theLead Agent in Phase I Testing ules on the PKS genes and put them
together so they’ll talk to one an-The company’s lead agent, KOS-862 epothilone field serves to under-
score the power of focused chemi-(Epothilone D), is a tubulin-stabiliz- other and create any molecule we
wish by genetic engineering.” Addsing compound that inhibits cancer cal synthesis. As an example of this,
a new chemical strategy to synthe-cell division. “This is the first small Myles, “Success in this area of
morphing actually opens up the pos-molecule in a clinical trial that was size many novel epothilones has just
been published by the Sloan-Ketter-produced in a heterologous host,” sibility of making combinatorial
polyketide libraries,” and opens withsays Katz. He adds that it also repre- ing group in the Journal of the Amer-
ican Chemical Society. “In this newsents the largest set of genes trans- it an assortment and collection of
potential drug candidates previ-ferred to another organism and ex- synthesis, we used olefin metathesis
to create a novel 10,11 dehydro-pressed. ously unavailable.
KOS-862 was synthesized in the epothilone D, which Kosan had dis-
Chemistry & Biology invites yourlaboratory of Samuel Danishef- covered earlier and termed epothi-
comments on this topic. Pleasesky, PhD, Department of Chemistry, lone 490,” says Danishefsky. “Our
write to the editors at chembiol@Columbia University, and Director total synthesis strategy makes it
cell.com.of the Laboratory for Bioorganic possible to generate totally novel
epothilone analogs in a highly con-Chemistry at Memorial Sloan-Ket- Alice A. McCarthy is a freelance science
tering Cancer Center (MSKCC). “He vergent way.” writer based in Magnolia, MA (alice@
alicemccarthy.com).is the man who first synthesized it In Limited but Good Company
Kosan is one of just a small group ofby total chemical synthesis,” says
Santi of the drug Danishefsky re- companies focused exclusively on
polyketide drug development andferred to as EpoD in his own lab and
one of several 12,13 desoxy epothi- discovery, which includes Biotica
Technology, Ltd, a 20-person spin-lones synthesized and evaluated by
MSKCC scientists. “We came upon off from the University of Cam-
bridge, England. “We are watchingthese compounds through chemical
synthesis, following our perception the progress of Kosan’s epothilone
D with some interest, as, if ap-that the epoxide linkages of the A
and B epothilones might be very proved, it would be the first small
molecule drug developed from thedamaging and not critical for activ-
ity,” he says. Accordingly, his syn- start to be produced by genetic en-
gineering,” says Simon Turner, PhD,thesis team deleted the epoxides
and got to the D series with far better Biotica CEO. Founded on the sci-
ence of Cambridge researchers Pe-biological profiles in mice than the
more common epothilones A and B. ter Leadlay and Jim Staunton,
Biotica has yet to identify a leadKOS-862 is in two ongoing phase
I trials, with a third just starting at agent for human testing, but its most
advanced discovery projects in-MSKCC. All of these phase I trials
are in patients with advanced solid clude an angiogenesis inhibitor and
an antiproliferative agent. And Gali-tumor malignancies with unsuc-
cessful treatment on other standard laeus Oy in Finland is working on
engineering novel polyketide ana-therapies. Early results suggest the
drug is well tolerated, though an op- logs such as the anthracycline anti-
cancer agents.timum therapeutic dose has yet to
be determined. Kosan is targeting In the epothilone field, though, Ko-
san’s KOS-862 is in the developmentthe end of 2002/early 2003 for start
of phase II efficacy trials. company of compounds both in
